Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles.

Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM.

ERJ Open Res. 2019 Jun 17;5(2). pii: 00082-2019. doi: 10.1183/23120541.00082-2019. eCollection 2019 Apr.

2.

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.

McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS.

Lancet Respir Med. 2019 Apr;7(4):325-335. doi: 10.1016/S2213-2600(18)30460-0. Epub 2019 Jan 24.

PMID:
30686767
3.

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.

4.

VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.

5.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

McColley SA, Konstan MW, Ramsey BW, Stuart Elborn J, Boyle MP, Wainwright CE, Waltz D, Vera-Llonch M, Marigowda G, Jiang JG, Rubin JL.

J Cyst Fibros. 2019 Jan;18(1):94-101. doi: 10.1016/j.jcf.2018.07.011. Epub 2018 Aug 23.

6.

Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis.

Trimble AT, Whitney Brown A, Laube BL, Lechtzin N, Zeman KL, Wu J, Ceppe A, Waltz D, Bennett WD, Donaldson SH.

J Cyst Fibros. 2018 Sep;17(5):650-656. doi: 10.1016/j.jcf.2018.01.001. Epub 2018 Jan 20.

PMID:
29371133
7.

Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.

Taylor-Cousar JL, Jain M, Barto TL, Haddad T, Atkinson J, Tian S, Tang R, Marigowda G, Waltz D, Pilewski J; VX14-809-106 Investigator Group.

J Cyst Fibros. 2018 Mar;17(2):228-235. doi: 10.1016/j.jcf.2017.09.012. Epub 2017 Nov 8.

8.

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group.

Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9. Erratum in: Lancet Respir Med. 2017 Aug;5(8):e28.

9.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.

PMID:
28011037
10.

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.

Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP; VX09-809-102 Study Group.

Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC.

11.

Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy.

Marigowda G, Liu F, Waltz D.

J Cyst Fibros. 2017 Mar;16(2):246-249. doi: 10.1016/j.jcf.2016.11.001. Epub 2016 Nov 25.

12.

Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.

Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; VX13-809-011 Part B Investigator Group *.

Am J Respir Crit Care Med. 2017 Apr 1;195(7):912-920. doi: 10.1164/rccm.201608-1754OC.

13.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.

Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D, Wainwright CE; VX-809 TRAFFIC and TRANSPORT study groups.

Lancet Respir Med. 2016 Aug;4(8):617-626. doi: 10.1016/S2213-2600(16)30121-7. Epub 2016 Jun 10.

14.

Use of the Vocera Communications Badge Improves Public Safety Response Times.

Joslin JD, Goldberger D, Johnson L, Waltz DP.

Emerg Med Int. 2016;2016:7158268. doi: 10.1155/2016/7158268. Epub 2016 Apr 4.

15.

Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.

Adams GN, Rosenfeldt L, Frederick M, Miller W, Waltz D, Kombrinck K, McElhinney KE, Flick MJ, Monia BP, Revenko AS, Palumbo JS.

Cancer Res. 2015 Oct 1;75(19):4235-43. doi: 10.1158/0008-5472.CAN-15-0964. Epub 2015 Aug 3.

16.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

17.

Novel outcome measures for clinical trials in cystic fibrosis.

Tiddens HAWM, Puderbach M, Venegas JG, Ratjen F, Donaldson SH, Davis SD, Rowe SM, Sagel SD, Higgins M, Waltz DA.

Pediatr Pulmonol. 2015 Mar;50(3):302-315. doi: 10.1002/ppul.23146. Epub 2014 Dec 30. Review.

18.

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group.

Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24.

PMID:
24973281
19.

Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

Rowe SM, Reeves G, Hathorne H, Solomon GM, Abbi S, Renard D, Lock R, Zhou P, Danahay H, Clancy JP, Waltz DA.

Chest. 2013 Jul;144(1):200-207. doi: 10.1378/chest.12-2431.

20.

The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers.

Kirsten A, Watz H, Pedersen F, Holz O, Smith R, Bruin G, Koehne-Voss S, Magnussen H, Waltz DA.

Eur Respir J. 2013 Jan;41(1):239-41. doi: 10.1183/09031936.00123612. No abstract available.

21.

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis.

Uluer AZ, Waltz DA, Kalish LA, Adams S, Gerard C, Ericson DA.

J Cyst Fibros. 2013 Jan;12(1):54-9. doi: 10.1016/j.jcf.2012.06.006. Epub 2012 Oct 7.

22.

Machine learning for the New York City power grid.

Rudin C, Waltz D, Anderson RN, Boulanger A, Salleb-Aouissi A, Chow M, Dutta H, Gross PN, Huang B, Ierome S, Isaac DF, Kressner A, Passonneau RJ, Radeva A, Wu L.

IEEE Trans Pattern Anal Mach Intell. 2012 Feb;34(2):328-45. doi: 10.1109/TPAMI.2011.108.

PMID:
21576741
23.

Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patients.

Bakkal S, Robinson SM, Ordonez CL, Waltz DA, Riley MA.

Microbiology. 2010 Jul;156(Pt 7):2058-67. doi: 10.1099/mic.0.036848-0. Epub 2010 Apr 8.

24.

Computer science. Automating science.

Waltz D, Buchanan BG.

Science. 2009 Apr 3;324(5923):43-4. doi: 10.1126/science.1172781. No abstract available.

PMID:
19342574
25.

MDCT evaluation of the prevalence of tracheomalacia in children with mediastinal aortic vascular anomalies.

Lee EY, Zurakowski D, Waltz DA, Mason KP, Riaz F, Ralph A, Boiselle PM.

J Thorac Imaging. 2008 Nov;23(4):258-65. doi: 10.1097/RTI.0b013e31817fbdf7.

PMID:
19204470
26.

Highlights of a workshop to discuss targeting inflammation in cystic fibrosis.

Banner KH, De Jonge H, Elborn S, Growcott E, Gulbins E, Konstan M, Moss R, Poll C, Randell SH, Rossi AG, Thomas L, Waltz D.

J Cyst Fibros. 2009 Jan;8(1):1-8. doi: 10.1016/j.jcf.2008.10.002. Epub 2008 Nov 20. Review.

27.

The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis.

Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS, Waltz DA, Ren CL.

Pediatr Pulmonol. 2008 Nov;43(11):1117-1123. doi: 10.1002/ppul.20914.

PMID:
18846559
28.

MDCT assessment of tracheomalacia in symptomatic infants with mediastinal aortic vascular anomalies: preliminary technical experience.

Lee EY, Mason KP, Zurakowski D, Waltz DA, Ralph A, Riaz F, Boiselle PM.

Pediatr Radiol. 2008 Jan;38(1):82-8. Epub 2007 Nov 16.

PMID:
18038169
29.

Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE.

Hum Gene Ther. 2007 Aug;18(8):726-32.

PMID:
17685853
30.

Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.

Dovey M, Aitken ML, Emerson J, McNamara S, Waltz DA, Gibson RL.

Chest. 2007 Oct;132(4):1212-8. Epub 2007 Jul 23.

PMID:
17646219
31.

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.

Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW.

Pediatr Pulmonol. 2007 Jul;42(7):610-23.

PMID:
17534969
32.

American Society of Transplantation executive summary on pediatric lung transplantation.

Faro A, Mallory GB, Visner GA, Elidemir O, Mogayzel PJ Jr, Danziger-Isakov L, Michaels M, Sweet S, Michelson P, Paranjape S, Conrad C, Waltz DA; American Society of Transplantation.

Am J Transplant. 2007 Feb;7(2):285-92. Epub 2006 Nov 15.

33.

The ISHLT transplant registry: moving forward.

Hertz MI, Boucek MM, Edwards LB, Keck BM, Rowe AW, Taylor DO, Trulock EP, Waltz DA.

J Heart Lung Transplant. 2006 Oct;25(10):1179-85. No abstract available.

PMID:
17045929
34.

Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric lung and heart-lung transplantation report--2006.

Waltz DA, Boucek MM, Edwards LB, Keck BM, Trulock EP, Taylor DO, Hertz MI.

J Heart Lung Transplant. 2006 Aug;25(8):904-11. No abstract available.

PMID:
16890110
35.

Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report--2006.

Boucek MM, Waltz DA, Edwards LB, Taylor DO, Keck BM, Trulock EP, Hertz MI; International Society for Heart and Lung Transplantation.

J Heart Lung Transplant. 2006 Aug;25(8):893-903. No abstract available.

PMID:
16890109
36.

Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report--2006.

Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, Hertz MI; International Society for Heart and Lung Transplantation.

J Heart Lung Transplant. 2006 Aug;25(8):869-79. Epub 2006 Jul 10. No abstract available.

PMID:
16890107
37.

Membranous obliterative bronchitis: a proposed unifying model.

Colin AA, Tsiligiannis T, Nosé V, Waltz DA.

Pediatr Pulmonol. 2006 Feb;41(2):126-32.

PMID:
16358340
38.

Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis.

Kalish LA, Waltz DA, Dovey M, Potter-Bynoe G, McAdam AJ, Lipuma JJ, Gerard C, Goldmann D.

Am J Respir Crit Care Med. 2006 Feb 15;173(4):421-5. Epub 2005 Nov 4.

PMID:
16272450
39.

Cutaneovisceral angiomatosis with thrombocytopenia.

Prasad V, Fishman SJ, Mulliken JB, Fox VL, Liang MG, Klement G, Kieran MW, Burrows PE, Waltz DA, Powell J, Dubois J, Levy ML, Perez-Atayde AR, Kozakewich HP.

Pediatr Dev Pathol. 2005 Jul-Aug;8(4):407-19. Epub 2005 Jul 19.

PMID:
16034654
40.

Tracheomalacia and tracheobronchomalacia in children and adults: an in-depth review.

Carden KA, Boiselle PM, Waltz DA, Ernst A.

Chest. 2005 Mar;127(3):984-1005. Review.

PMID:
15764786
41.

Hydroxychloroquine and surfactant protein C deficiency.

Rosen DM, Waltz DA.

N Engl J Med. 2005 Jan 13;352(2):207-8. No abstract available.

PMID:
15647591
42.

Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.

Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K.

Pediatr Pulmonol. 2005 Mar;39(3):209-18.

PMID:
15573395
43.

Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.

Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, Eaton RB.

Pediatrics. 2004 Jun;113(6):1573-81.

PMID:
15173476
44.

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE.

Chest. 2004 Feb;125(2):509-21.

PMID:
14769732
45.

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.

Geller DE, Rosenfeld M, Waltz DA, Wilmott RW; AeroDose TOBI Study Group.

Chest. 2003 Jan;123(1):28-36.

PMID:
12527599
46.

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B; Cystic Fibrosis Therapeutics Development Network Study Group.

Am J Respir Crit Care Med. 2003 Mar 15;167(6):841-9. Epub 2002 Dec 12.

PMID:
12480612
47.

A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.

Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC.

Hum Gene Ther. 2001 Oct 10;12(15):1907-16.

PMID:
11589832
48.
49.

Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis.

Slattery DM, Waltz DA, Denham B, O'Mahony M, Greally P.

Pediatr Pulmonol. 2001 May;31(5):383-8.

PMID:
11340685
50.

FEV(1) as a guide to lung transplant referral in young patients with cystic fibrosis.

Robinson W, Waltz DA.

Pediatr Pulmonol. 2000 Sep;30(3):198-202.

PMID:
10973037

Supplemental Content

Support Center